Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M609Revenue (TTM) $M140Net Margin (%)-23.1Altman Z-Score3.3
Enterprise Value $M466EPS (TTM) $-0.8Operating Margin %-23.5Piotroski F-Score3
P/E(ttm)--Beneish M-Score-3.0Pre-tax Margin (%)-23.1Higher ROA y-yN
Price/Book4.710-y EBITDA Growth Rate %--Quick Ratio3.4Cash flow > EarningsY
Price/Sales4.35-y EBITDA Growth Rate %--Current Ratio3.4Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %-130.4ROA % (ttm)-15.3Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-24.7Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M44.0ROIC % (ttm)--Gross Margin Increase y-yY

Gurus Latest Trades with VNDA

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
VNDAJohn Paulson 2016-09-30 Reduce-0.2%$10.99 - $17.05
($13.46)
$ 13.853%Reduce -43.72%2,175,000
VNDAJoel Greenblatt 2016-09-30 Add$10.99 - $17.05
($13.46)
$ 13.853%Add 90.46%27,244
VNDAJohn Paulson 2016-06-30 Reduce$8.23 - $11.35
($9.66)
$ 13.8543%Reduce -1.59%3,864,717
VNDAJoel Greenblatt 2016-06-30 Buy $8.23 - $11.35
($9.66)
$ 13.8543%New holding14,304
VNDAJohn Paulson 2016-03-31 Reduce$7.23 - $9.31
($8.23)
$ 13.8568%Reduce -0.49%3,927,000
VNDAJohn Paulson 2015-06-30 Reduce$9.09 - $13.42
($10.76)
$ 13.8529%Reduce -0.09%3,946,500
VNDAJohn Paulson 2015-03-31 Add0.02%$8.99 - $14.58
($11.3)
$ 13.8523%Add 8.97%3,950,000
VNDAJohn Paulson 2014-06-30 Add0.12%$9.7 - $16.96
($13.27)
$ 13.854%Add 129.80%3,200,000
VNDAJohn Paulson 2014-03-31 Buy 0.11%$10.5 - $18.71
($14.13)
$ 13.85-2%New holding1,392,500
VNDAFirst Eagle Investment 2013-09-30 Sold Out -0.024%$8.05 - $13.03
($10.66)
$ 13.8530%Sold Out0
VNDAFirst Eagle Investment 2013-06-30 Reduce-0.01%$3.93 - $13
($6.73)
$ 13.85106%Reduce -48.99%975,000
VNDAFirst Eagle Investment 2012-12-31 Add0.01%$3.03 - $4.16
($3.54)
$ 13.85291%Add 43.16%1,911,452
VNDAFirst Eagle Investment 2010-03-31 Add0.04%$10.01 - $12.38
($10.94)
$ 13.8527%Add 111.12%752,375
VNDAFirst Eagle Investment 2009-12-31 Buy 0.04%$9.59 - $11.84
($10.79)
$ 13.8528%New holding356,375
VNDAFirst Eagle Investment 2009-06-30 Sold Out $0.9 - $14.64
($7.49)
$ 13.8585%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

VNDA is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


VNDA: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Kelly James PatrickSVP, CFO & Treasurer 2017-01-03Sell10,895$15.51-10.7view
Polymeropoulos Mihael HristosPresident and CEO 2017-01-03Sell23,330$15.48-10.53view
Baroldi PaoloSVP & Chief Medical Officer 2017-01-03Sell16,300$15.51-10.7view
Gulino Richard L.SVP, General Counsel & Sec. 2017-01-03Sell10,900$15.51-10.7view
Flynn James E 2016-09-23Sell1,120,461$16.56-16.36view
Flynn James E 2016-09-19Sell547,886$15.66-11.56view
Polymeropoulos Mihael HristosPresident and CEO 2016-01-04Sell21,353$8.9654.58view
Kelly James PatrickSVP, CFO, Sec & Treasurer 2016-01-04Sell9,564$8.9654.58view
Baroldi PaoloSVP & Chief Medical Officer 2016-01-04Sell12,380$8.9654.58view
Flynn James E 2015-12-16Buy11,170$8.9754.4view

Quarterly/Annual Reports about VNDA:

News about VNDA:

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Cameron International, Envision Healthcare Holdings, Vanda Pharmaceutica Sep 20 2015 
Weekly CEO Sells Highlight: Walker & Dunlop, Arista Networks, Vanda Pharmaceuticals, and Synopsys May 31 2015 
John Paulson's Stocks Trading for Less Than He Paid for Them Jun 02 2014 
Best Performing Gurus of Past Six Months are John Paulson, First Eagle and Michael Price Jun 11 2013 
Vanda: This Company Has Great Assets But No Profits Jan 21 2012 
Vanda Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 10 2011 
Vanda Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 06 2010 
Vanda Pharmaceuticals Inc. Reports Operating Results (10-Q) May 10 2010 
Vanda Pharmaceuticals Inc. (VNDA) Acting CFO/Treasurer Stephanie Rast Irish sells 20,000 Shares Feb 23 2010 
Preserving Value: The Case for Voluntary Liquidation Jan 17 2010 

More From Other Websites
Merck KGaA Expands Distribution Deal with Roche (revised) Jan 17 2017
D.C.-area biotech stocks fall on Trump's tough talk on industry Jan 11 2017
Jefferies Has 5 Top Biotech Stocks to Buy for 2017 Jan 10 2017
VANDA PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Jan 09 2017
Vanda Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2016 Revenue Results and 2017... Jan 09 2017
Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : VNDA-US :... Jan 02 2017
Abbott Labs to Close St. Jude Acquisition Later this Week Jan 02 2017
Cempra (CEMP) Gets CRL from FDA for Pneumonia Candidate Dec 30 2016
Prima (PBMD) Reports Favorable Initial Melanoma Study Data Dec 30 2016
Shire Gets FDA Approval for Label Expansion of Adynovate Dec 28 2016
Seattle Genetics' Acute Myeloid Leukemia Drug on FDA Hold Dec 28 2016
Ionis/Biogen Spinraza Approved For Spinal Muscular Atrophy Dec 27 2016
Why Vanda Pharmaceuticals (VNDA) Might Be a Diamond in the Rough Dec 27 2016
Roche (RHHBY) Hemophilia A Drug Positive in Phase III Dec 23 2016
Teva Settles Foreign Bribery Charges with U.S. Government Dec 23 2016
Incyte/Merus Ink Collaboration for Bispecific Antibodies Dec 22 2016
Pfizer (PFE) Nimenrix Vaccine's Label Expanded in the EU Dec 21 2016
Vanda Pharmaceuticals, Inc. – Value Analysis (NASDAQ:VNDA) : December 21, 2016 Dec 21 2016
J&J Files for FDA Approval of Simponi Aria Label Expansion Dec 21 2016
Biogen (BIIB) Board Okays Hemophilia Business Spin-off Dec 21 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)